These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9123373)

  • 21. Single-center analysis of 468 first cadaveric kidney allografts with a uniform ATG-CsA sequential therapy.
    Giral M; Taddei C; Nguyen JM; Dantal J; Hourmant M; Cantarovich D; Blancho G; Ancelet D; Soulillou JP
    Clin Transpl; 1996; ():257-64. PubMed ID: 9286575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HLA-A, -B, and -DR matching contributes to graft survival in black recipients of renal allografts.
    Modiba MC; Wolf JS; Morse R; Lee A; Anderson B
    Transplant Proc; 1992 Oct; 24(5):1680-2. PubMed ID: 1412795
    [No Abstract]   [Full Text] [Related]  

  • 23. HLA-A antigen incompatibility and HLA-B antigen compatibility associated with enhanced kidney allograft survival in blood-transfused patients.
    Bućin D
    Exp Clin Immunogenet; 1986; 3(3):138-44. PubMed ID: 3274633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short and long-term results after pretransplant high-dose single ATG-fresenius bolus in cadaveric kidney transplantation.
    Kaden J; Strobelt V; May G
    Transplant Proc; 1998 Dec; 30(8):4011-4. PubMed ID: 9865279
    [No Abstract]   [Full Text] [Related]  

  • 25. Is cyclosporine a match for tissue typing centers? Role of the zero HLA-A, B, and DR mismatch effect.
    Cicciarelli J; Terasaki PI; Cecka M; Mickey MR
    Transplant Proc; 1987 Feb; 19(1 Pt 1):647-9. PubMed ID: 3274831
    [No Abstract]   [Full Text] [Related]  

  • 26. Good kidney transplant outcome in recipients with presensitization against HLA class II but not HLA class I.
    Süsal C; Opelz G
    Hum Immunol; 2004 Aug; 65(8):810-6. PubMed ID: 15336782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of HLA matching on graft survival in live donor kidney transplantations.
    Velidedeoğlu E; Bilgin N; Haberal M
    Transplant Proc; 1993 Dec; 25(6):3144-5. PubMed ID: 8266491
    [No Abstract]   [Full Text] [Related]  

  • 28. Quality of serological donor HLA typing: analysis of graft survival by HLA in renal transplantation recipients treated with cyclosporine.
    Thorogood J; Schreuder GM; Persijn GG; van Rood JJ
    Transplant Proc; 1992 Dec; 24(6):2485-7. PubMed ID: 1465839
    [No Abstract]   [Full Text] [Related]  

  • 29. Repeated mismatches may not impair survival of renal regrafts in recipients with 0% to 50% panel reactive antibodies.
    Mjörnstedt L; Konar J; Skarp I; Olausson M; Sandberg L; Tufvesson G
    Transplant Proc; 1992 Dec; 24(6):2469. PubMed ID: 1465834
    [No Abstract]   [Full Text] [Related]  

  • 30. Pre- and Posttransplant IgA Anti-Fab Antibodies to Predict Long-term Kidney Graft Survival.
    Amirzargar MA; Amirzargar A; Basiri A; Hajilooi M; Roshanaei G; Rajabi G; Solgi G
    Transplant Proc; 2015 May; 47(4):1110-3. PubMed ID: 26036531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elective vs systematic corticosteroid withdrawal in renal transplant recipients receiving triple drug therapy.
    Hiesse C; Rousseau P; Kriaa F; Larue JR; Charpentier B
    Transplant Proc; 1995 Feb; 27(1):1066-7. PubMed ID: 7878807
    [No Abstract]   [Full Text] [Related]  

  • 32. Pretransplant and posttransplant monitoring of anti-HLA class I IgG1 antibodies by ELISA identifies patients at high risk of graft loss.
    Monteiro F; Mineiro C; Rodrigues H; de Paula FJ; Kalil J
    Transplant Proc; 1997; 29(1-2):1433-4. PubMed ID: 9123368
    [No Abstract]   [Full Text] [Related]  

  • 33. Impact of HLA matching on the outcome of simultaneous pancreas-kidney transplantation.
    Berney T; Malaise J; Morel P; Toso C; Demuylder-Mischler S; Majno P; Bühler LH; Mentha G;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii48-53, ii62. PubMed ID: 15814550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
    Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
    Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beneficial effect of DR matching on cadaveric renal graft survival in Scandiatransplant.
    Leivestad T; Berger L; Thorsby E
    Transplant Proc; 1992 Dec; 24(6):2447-8. PubMed ID: 1465824
    [No Abstract]   [Full Text] [Related]  

  • 36. Mycophenolate mofetil eliminates the rationale for antilymphocyte induction therapy in nonhaploidentical living-donor kidney transplants.
    Shaffer D; Madras PN; Conway P; Davis C; Simpson MA; Monaco AP
    Transplant Proc; 1997; 29(1-2):342-3. PubMed ID: 9123031
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of DR and DR6 matching on cadaver kidney transplant survival.
    Reyman TA; Toledo-Pereyra LH
    Transplant Proc; 1987 Feb; 19(1 Pt 1):702-4. PubMed ID: 3274848
    [No Abstract]   [Full Text] [Related]  

  • 38. Cadaveric kidney transplantation in patients with lymphocytotoxic autoantibodies.
    Emonds MP; Dendievel J; Roels L; Waer M; Vanrenterghem Y; Vermylen C
    Transplant Proc; 1992 Dec; 24(6):2502-3. PubMed ID: 1465845
    [No Abstract]   [Full Text] [Related]  

  • 39. Excellent long-term survival of low-risk, first renal allografts using cyclosporine/azathioprine double therapy.
    Faull RJ; Bannister KM; Russ GR; Mathew TH; Clarkson AR
    Transplant Proc; 1999; 31(1-2):1155-6. PubMed ID: 10083516
    [No Abstract]   [Full Text] [Related]  

  • 40. The effect of HLA-A,B matching in cadaver grafts.
    Kilicturgay S; Tokyay R; Turan M; Haberal M
    Transplant Proc; 1992 Oct; 24(5):1678-9. PubMed ID: 1412794
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.